title: Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.
abstract: OBJECTIVE
  To ascertain the predictive value of Her-2/neu overexpression and p53 mutations, assessed by immunohistochemistry, in high-risk primary breast cancer (HRPBC) treated with high-dose chemotherapy (HDCT).
  
  
  METHODS
  We obtained paraffin-embedded tumor blocks from 146 HRPBC patients previously enrolled at our program onto clinical trials of HDCT for four to nine involved axillary lymph nodes, > or = 10 involved axillary nodes, or inflammatory carcinoma. All patients received the same HDCT regimen, with cyclophosphamide, cisplatin, and carmustine (STAMP-I), followed by autologous stem-cell transplantation. Median follow-up was 42 months (range, 5 to 90 months). The same pathologist, blinded to clinical outcome, reviewed all immunostained slides.
  
  
  RESULTS
  Positive results for Her-2/neu and p53 were found in 44.5% and 34% of the patients, respectively. Positivity for Her-2/neu was significantly associated with increased risk of relapse and death. No correlation was found between p53 mutations and relapse-free survival (RFS) or overall survival (OS). Multivariate analyses included Her-2/neu overexpression and the following variables previously identified as independent predictors of outcome in this population: tumor size, nodal ratio (number of involved nodes/number of dissected nodes), and hormone receptor status. All four variables had independent value.
  
  
  CONCLUSIONS
  Her-2/neu overexpression is an independent negative predictor of RFS and OS in HRPBC treated with HDCT. Its inclusion in our previously described predictive model increases the predictive capacity of this model for the low-risk subgroup. In contrast, p53 mutations lack predictive value in this setting.
authors.affiliation: University of Colorado Bone Marrow Transplant Program and Departments of Pathology and Biostatistics, University of Colorado, Denver 80262, USA. yago.nieto@uchsc.edu
authors.forename: Y
authors.initials: Y
authors.lastname: Nieto
authors.forename: P J
authors.initials: PJ
authors.lastname: Cagnoni
authors.forename: S
authors.initials: S
authors.lastname: Nawaz
authors.forename: E J
authors.initials: EJ
authors.lastname: Shpall
authors.forename: R
authors.initials: R
authors.lastname: Yerushalmi
authors.forename: B
authors.initials: B
authors.lastname: Cook
authors.forename: P
authors.initials: P
authors.lastname: Russell
authors.forename: J
authors.initials: J
authors.lastname: McDermit
authors.forename: J
authors.initials: J
authors.lastname: Murphy
authors.forename: S I
authors.initials: SI
authors.lastname: Bearman
authors.forename: R B
authors.initials: RB
authors.lastname: Jones
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D016009:Chi-Square Distribution; D005260:Female; D015870:Gene Expression; D016158:Genes, p53 / Q000235:genetics*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009154:Mutation; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D012307:Risk Factors; D016019:Survival Analysis; D014182:Transplantation, Autologous
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases